Study Summary
This trial tests how mild & moderate liver disease affects drug safety, how it's absorbed & how well it's tolerated.
- Liver Disease
- Healthy Subjects
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 1 Secondary · Reporting Duration: Up to 4 days
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
BI 690517 mild hepatic impairment (Child-Pugh A)
1 of 3
BI 690517 normal hepatic function
1 of 3
BI 690517 moderate hepatic impairment (Child-Pugh B)
1 of 3
Experimental Treatment
32 Total Participants · 3 Treatment Groups
Primary Treatment: BI 690517 mild hepatic impairment (Child-Pugh A) · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How much of a risk does BI 690517 mild hepatic impairment (Child-Pugh A) pose to individuals?
"With limited clinical evidence to support safety and efficacy, BI 690517 received a score of 1 for mild hepatic impairment (Child-Pugh A)." - Anonymous Online Contributor
How numerous are the participants of this research endeavor?
"Indeed, the information publicly available from clinicaltrials.gov affirms that recruitment for this study is ongoing. It was originally advertised on February 21st 2023 and has been recently modified on February 27th 2023, with a goal of enrolling 32 subjects between 2 medical centers." - Anonymous Online Contributor
Is there still capacity to enroll individuals in this experiment?
"The clinical trial is presently searching for participants, and its most recent iteration was posted on February 27th 2023. Furthermore, the original posting dates back to February 21st of that same year." - Anonymous Online Contributor